BioCentury
ARTICLE | Company News

Transcept, Purdue Pharma sales and marketing update

December 10, 2012 8:00 AM UTC

Transcept said it will provide $10 million and partner Purdue will provide $19 million for a direct-to-consumer marketing campaign for insomnia drug Intermezzo zolpidem tartrate. Transcept said the campaign would be executed during 1H13. Intermezzo is marketed in the U.S. to treat insomnia when a middle of the night awakening is followed by difficulty returning to sleep. The partners could not be reached for comment (see BioCentury, April 9). ...